Biocon Biologics is expanding its global biosimilars footprint, driven by new launches and market share gains in key therapy areas. The company’s U.S. presence has strengthened through partnerships such as Civica’s CalRx insulin initiative, while upcoming products like bDenosumab are set to deepen its global reach. With revenue growth supported by operational efficiency and scale, Biocon Biologics continues to serve over six million patients across 120 countries. CEO Shreehas Tambe says the focus remains on affordability, access, and innovation as the company builds a resilient, diversified biosimilar business across regulated and emerging markets.

See Full Page